Abstract
ABSTRACT
Background
Accurate estimation of appendicular skeletal muscle mass (ASM) is crucial for sarcopenia diagnosis, but device‐dependent approaches (dual‐energy X‐ray absorptiometry [DXA] or bioelectrical impedance analysis [BIA]) limit widespread application in community settings. Developing prediction equations using readily available anthropometric measurements and common laboratory data (such as serum creatinine) offers a practical alternative for large‐scale screening. However, no population‐based prediction equations using these accessible parameters have been developed specifically for Asian populations, where body composition differs significantly from Western cohorts.
Methods
We conducted a three‐phase investigation: Phase 1 validated existing NHANES‐derived equations across three cohorts (
n
= 13 582) from Taiwan (ILAS,
n
= 2780; NAHSIT,
n
= 6853) and Japan (NILS‐LSA,
n
= 3949); Phase 2 developed new population‐based equations using the NAHSIT cohort; and Phase 3 performed external validation of newly developed NAHSIT‐derived equations in an independent Japanese cohort (NILS‐LSA). Model performance was assessed using
R
‐squared, root mean square error (RMSE) and area under the receiver operating characteristic curve (AUC) for detecting low muscle mass based on Asian Working Group for Sarcopenia (AWGS) 2019 criteria.
Results
In Phase 1 external validation, existing equations showed acceptable to strong predictive accuracy across populations (
R
2
= 0.52–0.89). Equation 4 (incorporating sex, age, height and weight) demonstrated robust performance across ILAS (
R
2
= 0.80, RMSE = 1.88), NILS‐LSA (
R
2
= 0.86, RMSE = 1.51) and NAHSIT (
R
2
= 0.89, RMSE = 1.52) cohorts. For detecting low muscle mass using AWGS 2019 criteria, AUC values ranged from 0.79 to 0.91 in males and 0.76 to 0.89 in females across cohorts. In Phase 2, our newly developed population‐based Equation 4 achieved superior performance (
R
2
= 0.90, RMSE = 1.45) with minimal prediction bias (median error: 0.06, IQR: 1.81) and excellent diagnostic capability (AUC = 0.90 in both sexes; sensitivity/specificity: 0.85/0.80 in males and 0.87/0.80 in females). Phase 3 external validation in the independent Japanese cohort (NILS‐LSA) demonstrated robust cross‐population generalizability, with Equation 4 achieving the highest AUC values (0.90 in males and 0.85 in females).
Conclusions
Our three‐phase investigation has established and validated the first population‐based prediction equations for ASM estimation in Asian populations. These clinically accessible equations overcome device‐dependency limitations and enable practical, large‐scale sarcopenia screening in community settings, representing a significant advance for early identification of sarcopenia and promotion of healthy muscle aging across Asian populations.